Approvals for RNA-based drugs in the past decade. © IQVIA

With the opening of a production centRE for RNA vaccines and therapeutics, German CDMO Wacker Biotech is expanding its expertise in the field of RNA active ingredients.

Dr Marco Giuman, Co-Founder & CTO and Dr Konstantinos Antonopoulos, Co-Founder & CEO, Picture: mk2 GmbH

Mk2 Biotechnologies GmbH was founded in 2020 and is located in the Innovation and Start-up Centre IZB in Planegg-Martinsried.